Skip Navigation


Annals of Oncology Advance Access originally published online on March 8, 2006
Annals of Oncology 2006 17(8):1336-1337; doi:10.1093/annonc/mdl045
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/8/1336    most recent
mdl045v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ardine, M.
Right arrow Articles by Berruti, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ardine, M.
Right arrow Articles by Berruti, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

letter to the editor

Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?

The first 10% of the full text of this article appears below.

Osteonecrosis of the jaw (ONJ) is a serious event that uncommonly complicates the natural history of bone metastatic patients treated with bisphosphonates [1Go]. The pathogenesis of this adverse event is unknown and probably multifactorial [2Go, 3Go]. The mechanisms by which bisphosphonates may cause ONJ are unclear. It is commonly believed . . . [Full Text of this Article]

M. Ardine1, D. Generali2, M. Donadio1, S. Bonardi2, M. Scoletta3, A. M. Vandone1, M. Mozzati2, O. Bertetto1, A. Bottini2, L. Dogliotti4 and A. Berruti4,*

1 Oncologia Medica, Centro Oncologico Ematologico Subalpino, Azienda Ospedaliera San Giovanni, Torino; 2 Breast Unit, Azienda Ospedaliera Istituti Ospitalieri, Cremona; 3 Chirurgia Orale I Azienda Ospedaliera San Giovanni, Torino; 4 Oncologia Medica, Azienda Ospedaliera San Luigi, Orbassano, Italy

* (E-mail: alfredo.berruti@gmail.com)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
P. K. Palaska, V. Cartsos, and A. I. Zavras
Bisphosphonates and Time to Osteonecrosis Development
Oncologist, November 1, 2009; 14(11): 1154 - 1166.
[Abstract] [Full Text] [PDF]